17645-30-6

Basic information

• Product Name: 2-ButenaMide, N-phenyl-, (2E)-
• Synonyms: 2-ButenaMide, N-phenyl-, (2E)-
• CAS NO: 17645-30-6
• Molecular Formula: C₁₀H₁₁NO
• Molecular Weight: 161.20044
• Mol File: 17645-30-6.mol
• Article Data: 19

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-ButenaMide, N-phenyl-, (2E)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-ButenaMide, N-phenyl-, (2E)-(17645-30-6)
• EPA Substance Registry System: 2-ButenaMide, N-phenyl-, (2E)-(17645-30-6)

Safety Data

• Hazardous Substances Data: 17645-30-6(Hazardous Substances Data)

Upstream product

• 103-71-9 phenyl isocyanate 
• 107-93-7 (E)-but-2-enoic acid 
• 62-53-3 aniline 
• 625-35-4 trans-chrotonyl chloride 
• 102-01-2 N-phenylacetoacetamide 
• 142-04-1 aniline hydrochloride 
• 13140-15-3 N-phenyl-3-butenamide 
• 623-43-8 crotonic acid methyl ester 
• 80-58-0 2-Bromobutyric acid 
• 78957-08-1 (methylmethylene)ketene 
• 17680-03-4 1-(trimethylstannyl)prop-1-ene 
• 187737-37-7 propene 
• 1954-91-2 3-hydroxy-N-phenylbutansaeureamid 
• 5679-59-4 diphenylphosphazoanilide 

Downstream Products

• 1954-91-2 3-hydroxy-N-phenylbutansaeureamid 
• 61444-22-2 (R)-3-hydroxy-N-phenylbutanamide 
• 124095-27-8 (R)-3-hydroxy-N-phenylbutanamide 
• 1577258-10-6 (S)-3-(4-fluorophenyl)-N-phenylbutanamide 
• 74973-28-7 3,4,4-Trimethyl-pentanoic acid phenylamide 

Relevant articles and documents

-

-

Synthesis of 2,3-dihydroxy-3-(N-substituted carbamoyl)propylphosphonic acid derivatives as hybrid DOXP-fosmidomycin analogues

A six-step synthetic pathway has been established to access a series of racemic 2,3-dihydroxy-3-(N-substituted carbamoyl)propylphosphonic acid derivatives, designed to contain structural features common to both the natural substrate 1-deoxy-D-xylulose 5-p

Useful four-carbon synthons en route to monastrol analogs

A simple protocol has been established for the preparation of a family of crystalline N-aryl γ-hydroxycrotonamides, useful four-carbon synthons. These were further elaborated to analogs of monastrol having variant ester sidechains, that were evaluated for their anticancer activity employing the NCI 60 cell line panel.